Vaccinare
Novità sugli antigeni dei vaccini acellulari contro la pertosse
NEWS ON ANTIGENES OF ACELLULAR PERTUSSIS VACCINE
GIORGIO BARTOLOZZI
Dipartimento di Pediatria, Università di Firenze
Giugno 1999 - pagg. 379 -380
Abstract
Several components of Bordetella pertussis induce an immune response. Recent studies
have shown that some structural antigens (such as pertactine, antigens of the fimbriae 2
and 3) and the Bordetella pertussis toxine, but not the filamentous hemoagglutinine (till now
considered the main antigen), have a significant role in inducing the production of
protective antibodies.
This new evidence should inform the development of new vaccines against Bordetella
pertussis.
Classificazione MeSH
Bibliografia
1. Storsaeter J, Hallander HO, Gustafsson J,
Olin P: Levels of anti-pertussis antibodies related
to protection after household exposure
to Bordetella pertussis. Vaccine 16, 1907-16,
1998.
2. Cherry JD, Gornbein J, Heininger U, Stehr K: A search for serological correlates of immunity to Bordetella pertussis cough illnesses. Vaccine 16, 1901-6, 1998.
3. Helvett EL, Halperin SA: Serological correlates of immunity to Bordetella pertussis. Vaccine 16, 1899-900, 1998.
4. Trollfors B, Taranger J, Lagergard T, et al: A placebo-controlled trial of a pertussistoxoid vaccine. N Engl J Med 333, 1045-50, 1995.
5. Trollfors B, Taranger J, Lagergard T, et al: Immunization of children with pertussis toxoid decreases spread of pertussis within the family. Pediatr Infect Dis J 17, 196-9, 1998.
6. Olin P, Rassmussen F, Gustafsson J, et al: Randomized controlled trial of two-component. Three-component, and five-component acellular pertussis vaccines compared with whole-cell pertussis vaccine. Lancet 350, 1569-77, 1997.
7. Gustafsson J, Hollander HO, Olin P, et al: A controlled trial of a two-component acellular, a five-component acellular, and a wholecell pertussis vaccine. N Engl J Med 334, 349- 55, 1996.
8. Greco D, Salmaso S, Mastrantonio P, et al: A controlled trial of two acellular vaccines and one whole-cell vaccine against pertussis. N Engl J Med 334, 341-8, 1996.
9. Poland GA: Still more questions on pertussis vaccines. Lancet 350, 1564-5, 1997.
2. Cherry JD, Gornbein J, Heininger U, Stehr K: A search for serological correlates of immunity to Bordetella pertussis cough illnesses. Vaccine 16, 1901-6, 1998.
3. Helvett EL, Halperin SA: Serological correlates of immunity to Bordetella pertussis. Vaccine 16, 1899-900, 1998.
4. Trollfors B, Taranger J, Lagergard T, et al: A placebo-controlled trial of a pertussistoxoid vaccine. N Engl J Med 333, 1045-50, 1995.
5. Trollfors B, Taranger J, Lagergard T, et al: Immunization of children with pertussis toxoid decreases spread of pertussis within the family. Pediatr Infect Dis J 17, 196-9, 1998.
6. Olin P, Rassmussen F, Gustafsson J, et al: Randomized controlled trial of two-component. Three-component, and five-component acellular pertussis vaccines compared with whole-cell pertussis vaccine. Lancet 350, 1569-77, 1997.
7. Gustafsson J, Hollander HO, Olin P, et al: A controlled trial of a two-component acellular, a five-component acellular, and a wholecell pertussis vaccine. N Engl J Med 334, 349- 55, 1996.
8. Greco D, Salmaso S, Mastrantonio P, et al: A controlled trial of two acellular vaccines and one whole-cell vaccine against pertussis. N Engl J Med 334, 341-8, 1996.
9. Poland GA: Still more questions on pertussis vaccines. Lancet 350, 1564-5, 1997.